Cort

Recent Posts

Scouting for autoimmune / immunology assets

Challenge: A new venture fund reached out to Alacrita for support with identifying novel pharma assets available for in-licensing, for the purpose of founding a new start-up and enabling the further...
Learn More

Due diligence, valuation, and licensing of an infectious disease asset

Challenge: A former venture fund client identified a novel Phase 1-ready asset for treating a rare CNS infectious disease and was interested in licensing the asset and founding a new company to...
Learn More

Sales forecast for nanoparticle-drug-conjugate in small cell lung cancer

Challenge: A UK-based pharma company specializing in oncology drug development sought to understand the potential value of a nanoparticle drug product in small cell lung cancer (SCLC). Alacrita was...
Learn More

Inflammatory bowel disease primary market research & opportunity mapping

Challenge: A private venture-backed US biotech company was developing a biologic through late-stage drug discovery and wished to quantify the commercial opportunity for the product in treating anemia...
Learn More

Preclinical development support for a gene therapy

Challenge: A biotech company developing novel gene therapy approaches for in vivo cell trans-differentiation required an AAV gene therapy expert to serve on a scientific advisory board (SAB) tasked...
Learn More

Scouting for GI disease assets for in-licensing

Challenge: A disease area unit within a global biopharmaceutical company was charged with a mandate to seek out novel candidate assets in development to treat inflammatory bowel disease (IBD) and...
Learn More

IP portfolio triage of a live biotherapeutic product for a US TTO

Project Challenge: A US technology transfer office required support in evaluating its life science research programs to help direct internal funding towards its most commercially viable projects....
Learn More

Benchmarking deal terms & formulating negotiating positions for AI discovery company

Project Challenge: Our client was a company on which we had conducted due diligence for an investor approached us for support with a potential deal with an AI discovery company. The concept was to...
Learn More

Scouting for metabolic disease assets to license

Challenge: A venture capital portfolio company developing small molecule therapeutics for metabolic/obesity indications had made the strategic decision to supplement their internal product pipeline...
Learn More

Assessing the clinical development & regulatory pathway for a Phase 3 gene therapy product

Challenge Our client, a PE-backed specialty pharma company growing rapidly through M&A, was assessing a number of late-stage development projects to license/acquire. The company was considering a...
Learn More

Clinical due diligence on a company targeting CNS indications

Challenge A major VC fund asked Alacrita to conduct a clinical due diligence on a potential investment in a company targeting CNS indications. The target company was led by an executive with whom the...
Learn More

Viral vector manufacturing landscape and bottlenecks

Challenge: A national biomedical research agency requested Alacrita’s support with (1) a technical assessment of the agency’s own internal capabilities in AAV manufacturing, (2) a global landscape of...
Learn More